SNIPR Biome leverages CRISPR-Cas technology to develop microbial medicines for precision killing of bacteria and gene modification, addressing critical infectious diseases like antibiotic-resistant infections in cystic fibrosis and hematologic cancers. The company focuses on selective, ultra-rapid bacterial eradication while preserving the patient’s microbiome, with a pipeline targeting pathogens of high importance, including Pseudomonas aeruginosa and antibiotic-resistant bacteria.
Preferred startup development maturity for initial funding deployment.
CRISPR-based microbial interventions, precision killing of bacteria, and gene modification for therapeutic applications targeting antimicrobial resistance and infectious diseases
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...
